They can simply submit the safety data they already have from the HIV trials when FDA asks for it, together with the COVID-19 trial data... no problem here.

If you look back at the author's article history, you will notice that he is a disungenious douchebag who recently changed his stance on the company while he believed it to be overvalued at .50 last year.